|
DRUG-INDUCED LIVER INJURY |
|---|---|
| รหัสดีโอไอ | |
| Creator | Pajaree Sriuttha |
| Title | DRUG-INDUCED LIVER INJURY |
| Publisher | Faculty of Pharmacy, Silpakorn University |
| Publication Year | 2560 |
| Journal Title | Thai Bulletin of Pharmaceutical Science (TBPS) |
| Journal Vol. | 12 |
| Journal No. | 2 (July-December)2017 |
| Page no. | 69-83 |
| Keyword | drug-induced liver injury, RUCAM, risk factors |
| ISSN | 1686-9540 |
| Abstract | Drug-induced liver injury (DILI) has a low incidence of occurrence but it can cause serious outcomes. The clinical presentations of DILI are variables ranging from asymptomatic individuals with mildly elevated liver enzymes to fulminant liver failure leading to death. DILI can result from either intrinsic or idiosyncratic mechanism. Exclusion of other possible etiologies according to the pattern of liver injury is necessary for the diagnosis. Moreover, diagnostic algorithm namely the Rousel Uclaf Causality Assessment Method (RUCAM) may be used as a tool to identify DILI in the suspected case. Discontinuation of the suspected agent should be done as soon as DILI is detected. Management of DILI is usually symptomatic treatment and identification of risk factors to prevent progression. Careful monitoring of alanine aminotransferase serum level might be needed in some cases. The best way to prevent DILI is to educate patients of the signs and symptoms of severe liver injury such as right upper quadrant abdominal pain, nausea, vomiting and jaundice. This article describes the epidemiology, risk factors, clinical signs & symptoms, causative drugs and assessment of DILI in order to assist the pharmacists in managing DILI. |
